Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amazon-Express Scripts Partnership? PBM Sees Opportunity In Uninsured Market

Executive Summary

Express Scripts points to a relatively untapped market of 30m uninsured individuals who could be reached through a collaboration with Amazon if the e-commerce giant ventures into Rx drug sales.

You may also be interested in...



Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments

US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.

Biopharma Investing In Better Success Rates Via AI, Data And New Modalities

Biopharma executives and investors gathered in San Diego on Feb. 28 and March 1 to talk about finding and funding innovation with a focus on novel technology and artificial intelligence that can improve drug discovery and development success rates.

J&J Shows Grace Under Pressure From Biosimilars And Other Threats

Oncology stars Darzalex and Imbruvica lift a strong fourth quarter, but Remicade biosimilars and pricing discounts continue to threaten to take a bite out of future performance. Tax reform and Amazon's potential entry into healthcare could also affect the diversified firm.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel